TPST vs. CRMD, NATR, MRSN, ADCT, RANI, ANL, ENTA, ME, ATAI, and AQST
Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include CorMedix (CRMD), Nature's Sunshine Products (NATR), Mersana Therapeutics (MRSN), ADC Therapeutics (ADCT), Rani Therapeutics (RANI), Adlai Nortye (ANL), Enanta Pharmaceuticals (ENTA), 23andMe (ME), Atai Life Sciences (ATAI), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical preparations" industry.
Tempest Therapeutics (NASDAQ:TPST) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings.
22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 3.3% of Tempest Therapeutics shares are owned by insiders. Comparatively, 3.6% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Tempest Therapeutics received 78 more outperform votes than CorMedix when rated by MarketBeat users. However, 71.43% of users gave CorMedix an outperform vote while only 64.14% of users gave Tempest Therapeutics an outperform vote.
Tempest Therapeutics has higher earnings, but lower revenue than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, CorMedix had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 3 mentions for CorMedix and 2 mentions for Tempest Therapeutics. CorMedix's average media sentiment score of 1.07 beat Tempest Therapeutics' score of 0.94 indicating that CorMedix is being referred to more favorably in the news media.
Tempest Therapeutics has a beta of -1.65, indicating that its share price is 265% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500.
CorMedix's return on equity of -77.17% beat Tempest Therapeutics' return on equity.
Tempest Therapeutics currently has a consensus target price of $25.00, suggesting a potential upside of 653.01%. CorMedix has a consensus target price of $13.00, suggesting a potential upside of 146.68%. Given Tempest Therapeutics' higher possible upside, analysts plainly believe Tempest Therapeutics is more favorable than CorMedix.
Summary
CorMedix beats Tempest Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Tempest Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tempest Therapeutics Competitors List
Related Companies and Tools
